<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654433</url>
  </required_header>
  <id_info>
    <org_study_id>UCBT-002</org_study_id>
    <secondary_id>BB-IND#13502</secondary_id>
    <nct_id>NCT00654433</nct_id>
  </id_info>
  <brief_title>ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases</brief_title>
  <acronym>UCBT-002</acronym>
  <official_title>A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldagen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a
      possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101)
      will be separated from the cord blood unit and given approximately 4 hours after the standard
      cord blood transfusion.

      The study will test if the supplemental cells will increase the speed at which normal levels
      of circulating blood cells are re-established after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the
      child's normal cells including their bone marrow (which forms blood cells) in order to
      prepare their body for the umbilical cord blood transplant. The cord blood transplant is
      intended to rescue your child's bone marrow from the bad effects of the procedure. The child
      will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell
      called ALD-101.

      The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly
      after transplant. This would shorten the period of time that the transplanted subject would
      be at risk for infection and bleeding and would also decrease the number of red blood cell
      and platelet transfusions needed.

      ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with
      genetic diseases and malignancy in one previous clinical study that is on-going.

      The main purpose of this research study is to test whether a portion of cord blood cells that
      have been separated from a cord blood unit (ALD-101) will increase the speed at which normal
      levels of circulating blood cells are re-established after transplant. This is the
      experimental part of this study. ALD-101 is also being tested to see if it is safe.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated - Sponsor Decision
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inherited metabolic diseases</measure>
    <time_frame>180 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of ALD-101 in accelerating neutrophil engraftment</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of adjuvant therapy of ALD-101 in infusional toxicity, adverse events, and primary graft failure.</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Inherited Metabolic Diseases</condition>
  <condition>Lysosomal Storage Disorders</condition>
  <condition>Peroxisomal Storage Diseases</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Mucopolysaccharidosis</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD-101</intervention_name>
    <description>A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of inherited metabolic diseases; including the following:

               -  Hurler Syndrome (MPS I)

               -  Hurler-Scheie Syndrome

               -  Hunter Syndrome (MPS II)

               -  Sanfilippo Syndrome A and B(MPS III)

               -  Maroteaux-Lamy Syndrome (MPS VI)

               -  Krabbe Disease (Globoid Leukodystrophy)

               -  Metachromatic Leukodystrophy (MLD)

               -  Adrenoleukodystrophy (ALD and AMN)

               -  Sandhoff Disease

               -  Tay Sachs Disease

               -  Pelizaeus Merzbacher (PMD)

               -  Niemann-Pick Disease

               -  Alpha-mannosidosis

               -  I-Cell Disease (ML II)

               -  Fucosidosis

               -  GM I Gangliosidosis

               -  Canavan Disease

          -  must be &lt;16 years of age at the time of study enrollment

          -  must have a good performance status (Lansky â‰¥80%)

          -  must have adequate function of other organ systems including: kidney, liver, heart and
             lungs

          -  must have given valid written informed consent

          -  must have a minimum life expectancy of at least 6 months

          -  must be determined to be a good candidate for a standard umbilical cord blood
             transplant

          -  must have an IQ &gt;70 or if too young for IQ testing the potential to reach this
             endpoint by age 5

        Exclusion Criteria:

          -  HIV, Hepatitis B and/or Hepatitis C positive

          -  concurrently involved in any other clinical study that affects engraftment or immune
             reconstitution

          -  uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain
             stem involvement

          -  uncontrolled infections

          -  prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12
             months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Hinson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aldagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Kurtzberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aldagen.com</url>
    <description>Sponsor's Website</description>
  </link>
  <reference>
    <citation>Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant. 2008 Jan;41(2):99-108. doi: 10.1038/sj.bmt.1705970. Epub 2008 Jan 7. Review.</citation>
    <PMID>18176609</PMID>
  </reference>
  <reference>
    <citation>Martin PL, Carter SL, Kernan NA, Sahdev I, Wall D, Pietryga D, Wagner JE, Kurtzberg J. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006 Feb;12(2):184-94.</citation>
    <PMID>16443516</PMID>
  </reference>
  <reference>
    <citation>Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics. 2006 Sep;118(3):e879-89. Epub 2006 Aug 21.</citation>
    <PMID>16923928</PMID>
  </reference>
  <reference>
    <citation>Gentry T, Deibert E, Foster SJ, Haley R, Kurtzberg J, Balber AE. Isolation of early hematopoietic cells, including megakaryocyte progenitors, in the ALDH-bright cell population of cryopreserved, banked UC blood. Cytotherapy. 2007;9(6):569-76.</citation>
    <PMID>17882722</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hurler Syndrome</keyword>
  <keyword>MPS I</keyword>
  <keyword>Hurler-Scheie Syndrome</keyword>
  <keyword>Hunter Syndrome</keyword>
  <keyword>MPS II</keyword>
  <keyword>Sanfilippo Syndrome</keyword>
  <keyword>MPS III</keyword>
  <keyword>Maroteaux-Lamy Syndrome</keyword>
  <keyword>MPS VI</keyword>
  <keyword>Krabbe Disease</keyword>
  <keyword>Globoid Leukodystrophy</keyword>
  <keyword>Metachromatic Leukodystrophy</keyword>
  <keyword>MLD</keyword>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>ALD</keyword>
  <keyword>Adrenomyeloneuropathy</keyword>
  <keyword>AMN</keyword>
  <keyword>Sandhoff Disease</keyword>
  <keyword>Tay Sachs Disease</keyword>
  <keyword>Pelizaeus Merzbacher</keyword>
  <keyword>PMD</keyword>
  <keyword>Niemann-Pick Disease A</keyword>
  <keyword>Niemann-Pick Disease B</keyword>
  <keyword>Alpha-mannosidosis</keyword>
  <keyword>Inherited metabolic diseases</keyword>
  <keyword>Inborn errors of metabolism</keyword>
  <keyword>Lysosomal storage diseases</keyword>
  <keyword>Peroxisomal storage diseases</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Umbilical cord blood transplantation</keyword>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Mucopolysaccharidosis III</keyword>
  <keyword>Mucopolysaccharidosis VI</keyword>
  <keyword>I Cell disease</keyword>
  <keyword>Fucosidosis</keyword>
  <keyword>GM1 Gangliosidosis</keyword>
  <keyword>Canavan Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

